1. Home
  2. IMNM vs SYBT Comparison

IMNM vs SYBT Comparison

Compare IMNM & SYBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

N/A

Current Price

$19.53

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Logo Stock Yards Bancorp Inc.

SYBT

Stock Yards Bancorp Inc.

N/A

Current Price

$75.08

Market Cap

2.4B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
IMNM
SYBT
Founded
2006
1904
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.4B
IPO Year
2020
2009

Fundamental Metrics

Financial Performance
Metric
IMNM
SYBT
Price
$19.53
$75.08
Analyst Decision
Strong Buy
Hold
Analyst Count
16
6
Target Price
$35.20
★ $90.20
AVG Volume (30 Days)
★ 1.3M
135.9K
Earning Date
11-05-2026
10-28-2026
Dividend Yield
N/A
★ 1.74%
EPS Growth
★ 51.40
22.11
EPS
N/A
★ 2.55
Revenue
$6,941,000.00
★ $23,406,000.00
Revenue This Year
N/A
$15.13
Revenue Next Year
$18,747.97
$8.33
P/E Ratio
★ N/A
$29.76
Revenue Growth
N/A
★ 3.37
52 Week Low
$13.53
$61.51
52 Week High
$30.06
$89.22

Technical Indicators

Market Signals
Indicator
IMNM
SYBT
Relative Strength Index (RSI) 30.12 34.54
Support Level $19.39 $74.73
Resistance Level $23.48 $82.14
Average True Range (ATR) 1.12 1.55
MACD -0.27 -0.20
Stochastic Oscillator 13.81 8.32

Price Performance

Historical Comparison
IMNM
SYBT

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About SYBT Stock Yards Bancorp Inc.

Stock Yards Bancorp Inc operates as a bank holding company providing commercial banking and wealth management services. Its Commercial Banking segment offers loan and deposit products to consumers and businesses, including retail and mortgage lending, deposit services, online and mobile banking, private banking, commercial and real estate lending, treasury and merchant services, international and correspondent banking, credit cards, and brokerage services through a third-party broker-dealer. Its Wealth Management and Trust (WM&T) segment provides investment management, financial and retirement planning, trust and estate services, and retirement plan management, with WM&T revenue distinguishing the company from similarly sized community banks.

Share on Social Networks: